Background-There is some controversy concerning the efficacy of low dose a interferon therapy in chronic hepatitis C. Aims-To evaluate the effectiveness of treatment with low doses ofa interferon in chronic hepatitis C. Patients-One hundred and forty one patients with anti-HCV positive chronic active hepatitis C from six hospitals were enrolled in the study. 
Abstract
Background-There is some controversy concerning the efficacy of low dose a interferon therapy in chronic hepatitis C. Aims-To evaluate the effectiveness of treatment with low doses ofa interferon in chronic hepatitis C. Patients-One hundred and forty one patients with anti-HCV positive chronic active hepatitis C from six hospitals were enrolled in the study. Methods-Patients were randomised to treatment with 5 MU (group A) or 1-5 MU (group B) injections. The dose was reduced in responders from group A or increased in non-responders from group B to maintain treatment with the miniimal effective dose. Patients were treated for 48 weeks and followed up for 24 additional weeks with no treatment. Normalisation of alanine aminotransferase (ALT) was used to evaluate response. Results-A sustained response was seen in eight patients from group A (12%) and in 15 (21%) from group B. This difference was not statistically significant. Increasing the dose of interferon led to sustained response in only five of 58 patients (90/o) from group B who did not respond to 1-5 MU injections. In contrast, 15 of 21 patients (71%) in whom ALT remained normal with 1.5 MU injections developed a sustained response. By multivariate analysis sustained response seemed associated with young age and was more frequent in patients with genotype 3 HCV infection. Sustained response was preceded by a rapid normalisation of ALT and was inversely related to the amount of a interferon necessary to maintain ALT at low values during treatment. Conclusions-Some patients with chronic hepatitis C are very sensitive to a interferon and can be successfully treated with low doses. Treatment with higher doses may be effective in a minority of patients who do not respond to low doses. (Gut 1996; 38: 603-609) Keywords: hepatitis C therapy, hepatitis C virus, interferon.
Chronic infection with the hepatitis C virus (HCV) is the main cause of chronic hepatitis in Western countries and in Japan.1-3 Chronic hepatitis C is a serious condition because it may lead to development of cirrhosis of the liver and hepatocellular carcinoma. [4] [5] [6] [7] Administration of ao interferon is currently accepted as a treatment for chronic hepatitis C because ao interferon inhibits HCV replication and induces remission of the activity of the disease in some cases. [8] [9] [10] [11] [12] Eradication of the infection after a interferon therapy has recently been reported. '3 However, important problems concerning ax interferon therapy in chronic hepatitis C remain unsolved. Many patients do not respond to this treatment and many others relapse almost immediately after withdrawal of the treatment. In addition, ax interferon is expensive and often causes adverse reactions, which occasionally are serious.14 As most of the unwanted side effects of interferon are dose related,'5 treatment with low doses might be preferable. However, it is uncertain if low dose interferon therapy is effective in chronic hepatitis C. In a multicentre study, Davis et This multicentre randomised study aimed to evaluate the effectiveness of low dose interferon therapy in chronic hepatitis C. To this purpose, a large number of patients were randomised to be treated with decreasing or increasing doses of interferon depending on the response to comparatively high (5 MU per injection) or low (1-5 MU) doses given initially, respectively.
Methods

PATIENTS
One hundred and forty one consecutive patients with chronic active hepatitis C participated in the study. They (Table III) .
In contrast, relapse upon interferon withdrawal seemed directly related to the amount Rapid normalisation of ALT after the start of treatment was associated with response. Normalisation ofALT after four or eight weeks of treatment was more frequent in responders (47% and 69% respectively), particularly in those with sustained response (56% and 78%), than in non-responders (3% and 4%). These differences were statistically significant. The frequency of rapid normalisation of ALT in sustained responders was somewhat greater than in transient responders but the difference was not statistically significant (Table IV) .
Responders and non-responders were compared to investigate factors associated with response (Table V) . Univariate analysis showed that responders were significantly younger than non-responders. History of intravenous drug abuse in the past was more common in responders. No significant differences in serum aspartate aminotransferase (AST) nor ALT activity were found but platelet and white blood cell counts were significantly higher in responders. The degree of histological severity was similar in responders and non-responders. Multivariate analysis showed that only age had independent predictive value of response. Univariate analysis of baseline features disclosed several differences between patients with and without sustained response. Sustained responders were younger and their platelet count and AST/ALT ratio were higher than in non-sustained responders. History of intravenous use of drugs was more frequent in sustained responders. The degree of histological severity was similar in both groups (Table VI) . Sustained response occurred, however, in 16 of 71 patients (23%) with preserved lobular architecture but in only seven of 70 (10%) with changed lobular architecture by the presence of bridging fibrosis or cirrhosis (difference between proportions 0. 125, 95% confidence intervals 00054 to 0.245, p=0.04). Multivariate analysis showed that only age was independently associated with sustained response.
Fifty four patients recruited at a single centre were screened for specific antibodies against HCV genotypes 1, 2, and 3. Thirty two (59%) reacted for type 1, one (2%) for type 2, five (9%) for type 3, five (9%) for genotypes 1, and two and 11 (20%) did not react or gave non-type specific reaction. The response to interferon in these 54 patients did not differ from that seen in the remaining 87 nonscreened patients recruited in other centres. Table VII shows the relation between HCV serotype and response to treatment. The proportion of patients who showed sustained response was significantly higher in patients with HCV genotype 3 or with an unidentified HCV genotype than in those infected with genotype 1 (Fisher's exact test, p=0.0048 and p=0*012 respectively). Of the 10 patients with sustained response, seven were treated with low dose interferon and four of them were infected by serotype 3 of HCV. In patients infected with HCV serotype 1, a sustained response after treatment with 1.5 MU injections was achieved in one case only.
HCV-RNA was investigated in serum samples taken before, during, and after treatment in the 54 patients screened for HCV serotypes. HCV-RNA was positive in all the cases before treatment. The proportion of patients in whom HCV-RNA became negative was greater in responders than in nonresponders (Table VIII) although three patients with sustained biochemical response still had detectable HCV-RNA in serum by nested polymerase chain reaction six months after completion of treatment. However, HCV-RNA became negative when these patients were re-tested one year later.
The rate of negative values of HCV-RNA seen after 12 weeks of treatment, at the end of treatment, and at the end of follow up in groups A and B was similar. (14) *Quantitative data are expressed as mean (SD). Abbreviations as in Table V .
Discussion
The potential value of a interferon therapy for the treatment of chronic non-A, non-B hepatitis was recognised in 1986, several years before the identification of HCV as the agent responsible for this disease.27 To assess the effectiveness of this treatment several controlled trials were set up and a recent meta analysis of these studies showed that a interferon can induce remission of the disease in about one half of treated patients although one half of responders will relapse when the treatment is stopped.28 In this study only 22 of 141 patients (1 5.6%) had a sustained response. This low proportion of responders is possibly due to patient selection because this study did not include patients with a low index of histological activity or chronic persistent hepatitis, who are believed to respond better to interferon.29 30 In fact, about one half of the patients selected for inclusion had either cirrhosis or chronic active hepatitis with bridging fibrosis and distorted lobular architecture, which are factors associated with a poor response to interferon therapy.29 31 32 Previous studies have suggested that, beside these histopathological features, the response to a interferon therapy may also be related to other circumstances. Among host related factors, old age,173334 long duration of the disease,3235 excessive body weight,3035 increased y glutamyltranspeptidadse,34 36 (22) 32 (59) detected in serum1039 have also emerged as important determinants of response. The dose of interferon and the duration of treatment can also influence the effectiveness of the treatment. The probability of permanent response seems greater if treatment is given for at least 12 months4041 and a high rate of sustained response in patients treated for 60 weeks has recently been reported. 42 The influence on response of the dose of interferon is more controversial because the results of studies showing that low dose is less effective than high dose therapy16-18 do not agree with other findings. '9 2041 To evaluate the influence of the dose administered on the final result of the treatment is an important issue because a interferon is expensive and often produces undesirable side effects, which are dose related.
The main objective of this study was to compare the effectiveness of two different schedules of a interferon therapy given for 48 weeks. To this purpose, a large group of patients with chronic active hepatitis C were randomised to receive a interferon at increasing or decreasing doses, starting from 1.5 MU or 5 MU per injection respectively, according to response. In contrast with other studies aimed at comparing fixed doses of interferon, the design of this trial permitted the administration of increasing amounts of interferon in those patients who failed to respond to lower doses, according to a strategy that may be effective in some patients. 43 There were no differences in the rate of response seen in patients treated with low, increasing dose in comparison with those treated with high, decreasing dose. In fact, the proportion of patients who responded, either transiently or permanently, was slightly greater in patients who started treatment with a low dose of interferon. As patients from both groups were comparable, it may be suggested that the effectiveness of the two therapeutic schedules evaluated in this study was similar.
Beside the possible role of low dose interferon therapy in chronic hepatitis C, other aspects of this study deserve further comment. Firstly, about two thirds of the patients who developed a sustained response were able to respond or to maintain ALT, or both below the upper normal limit with 1. 27 (84) At the end of therapy n (%/o) 5 (50) 9 (75) 27 (84) At the end of follow up n (%/o) 3 (30) 12 (100) 29 (91) interferon. In contrast, rapid normalisation of ALT was very rare in non-responders from the two study groups. These findings suggest that some patients with chronic HCV infection are very sensitive to interferon whereas other patients are refractory to this treatment. Distinction between these two categories has important implications. In this study the small number of patients who presented a sustained response to low dose interferon made difficult the identification of the features that characterise sustained responders. Comparison of sustained responders, most of whom achieved response with low dose treatment, with non-sustained responders, showed that young age, obvious parenteral exposure to infection, and particularly hiptory of addiction to intravenous drugs in the past, high AST/ALT ratio, and preserved lobular architecture were associated with complete response. Each of these variables has been recognised as a marker of favourable response in previous studies where patients received higher doses of interferon.30 In this study, however, logistic regression analysis showed that only young age was independently related to good response.
The influence of virological factors on the response to treatment was analysed in more than one third of the patients by testing for HCV serotype and serum HCV-RNA. Sustained response, even to low dose of interferon, seemed associated with infection with HCV serotype 3 whereas most patients infected with HCV serotype 1 did not respond or relapsed. These findings are in agreement with recent observations from other large serological surveys of patients with chronic hepatitis C treated with different interferon schedules. [45] [46] [47] In these studies it has been shown that aL interferon therapy is less effective in patients with chronic hepatitis caused by serotype 1 HCV than in patients infected by other HCV serotypes.
There is increasing evidence that a low level of viraemia is associated with longterm response to interferon therapy in chronic hepatitis C.10 39 48 Unfortunately, serum HCV-RNA was not assessed because properly processed and stored serum samples49 obtained at baseline were not available from many patients. We have recently reported, however, a good correlation between low HCV-RNA serum concentration and a satisfactory response to interferon in a large series of patients from our hospital who otherwise presented similar features to those included in this study.50 Therefore, the presence of low levels of viraemia in sustained responders from the present series is likely.
As noted previously,'9 serum HCV-RNA sequences were detected by nested polymerase chain reaction despite sustained biochemical remission in three of 10 patients. Although these subjects cleared HCV-RNA when tested one year later, the meaning and the prognostic implications of the presence of HCV-RNA in patients undergoing normalisation of ALT under interferon therapy is currently uncertain.
In summary, administration of 1-5 MU of ox interferon three times a week for 48 weeks was sufficient to induce sustained biochemical remission in about 15% of patients with chronic active hepatitis C in an area where genotype 1 is highly prevalent. Response to such a low dose of interferon can be expected in young patients infected with HCV genotype 3 and, possibly, low level of viraemia. Sustained response was heralded by rapid normalisation of ALT. Increasing the dose of interferon induced response in some patients who did not respond rapidly to low doses but most of them relapsed upon interferon withdrawal. Initial treatment with 5 MU injections followed by tapered doses in responding patients did not increase the efficiency of treatment with 1X5 MU initial doses. Failure of aL interferon therapy is likely in patients with chronic active hepatitis C who do not respond rapidly to low dose ax interferon therapy. In these patients, treatments other than at interferon given alone must be prospectively investigated. As relapse may still occur in patients responding to 48 week low dose therapy, treatment for longer periods of time deserves furhier evaluation.
